MODTX — Modus Therapeutics Holding AB Income Statement
0.000.00%
Last trade - 00:00- SEK45.64m
- SEK41.26m
Annual income statement for Modus Therapeutics Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.02 | 20.7 | 18 | 16.4 | 15.8 |
| Operating Profit | -6.02 | -20.7 | -18 | -16.4 | -15.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -6.02 | -20.7 | -18.3 | -17.9 | -15.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.02 | -20.7 | -18.3 | -17.9 | -15.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.02 | -20.7 | -18.3 | -17.9 | -15.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.02 | -20.7 | -18.3 | -17.9 | -15.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.374 | -1.67 | -1.14 | -1.01 | -0.433 |
| Dividends per Share |